サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1655602

前立腺がん治療薬の世界市場

Prostate Cancer Therapeutics

出版日
ページ情報
英文 212 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
前立腺がん治療薬の世界市場
出版日: 2025年02月14日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 212 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

前立腺がん治療薬の世界市場は2030年までに264億米ドルに達する見込み

2024年に180億米ドルと推定される前立腺がん治療薬の世界市場は、分析期間2024-2030年にCAGR 6.6%で成長し、2030年には264億米ドルに達すると予測されます。本レポートで分析したセグメントの一つであるホルモン療法は、CAGR6.8%を記録し、分析期間終了時には210億米ドルに達すると予測されます。標的療法分野の成長率は、分析期間中CAGR 5.8%と推定されます。

米国市場は50億米ドルと推定、中国はCAGR 6.0％で成長予測

米国の前立腺がん治療薬市場は2024年に50億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに40億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは6.0%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ6.2％と5.0％と予測されています。欧州では、ドイツがCAGR 5.1%で成長すると予測されています。

世界の前立腺がん治療薬市場- 主要動向と促進要因のまとめ

前立腺がんに対する現在の治療アプローチは？

前立腺がん治療薬は、前立腺がんを管理・治療するために考案された幅広い治療法を包含しており、前立腺がんは世界中で最も一般的ながんの1つです。主な治療アプローチには、手術、放射線療法、ホルモン療法、化学療法、そして最近では免疫療法や標的療法があります。根治的前立腺摘除術などの手術療法は前立腺を摘出するもので、限局したがんに推奨されます。放射線療法は、外部照射またはブラキセラピーによって行われ、高エネルギー線でがん細胞を標的とします。ホルモン療法、またはアンドロゲン除去療法（ADT）は、前立腺がんの成長を促進する男性ホルモンのレベルを低下させる。化学療法は、早期にはあまり用いられないが、進行した前立腺がんやホルモン抵抗性の前立腺がんに用いられます。これらの治療は、効果を最大化し、より包括的に病気を管理するために、しばしば併用されます。

新しい治療法は前立腺がん治療の情勢をどのように変えているのか？

新たな治療法は、より的を絞った個別化治療の選択肢を提供することで、前立腺がんの治療状況に革命をもたらしつつあります。最も有望な分野の1つは、エンザルタミドやアパルタミドなどの新規アンドロゲン受容体阻害剤の開発であり、これらはがんの増殖を促進するシグナルを遮断する効果が高いです。免疫療法、特に免疫チェックポイント阻害剤の使用も、前立腺がんでの成功は他のがんに比べて限定的ではあるが、人気を集めています。前立腺特異的膜抗原（PSMA）を発現する細胞に標的放射線を照射するルテチウム177-PSMA-617のような放射性リガンド療法の使用も大きな進歩です。さらに、オラパリブのようなPARP阻害剤は、特定の遺伝子変異を有する患者に有効性を示し、個別化治療の新たな道を提供しています。これらの革新的な治療法は、生存率を向上させるだけでなく、従来の治療に伴う副作用を軽減することで、患者のQOLを向上させています。

前立腺がん治療薬の未来を牽引するイノベーションとは？

前立腺がん治療薬の未来は、いくつかの重要なイノベーションと研究の進歩によって形作られています。個人と腫瘍の遺伝子プロファイルに基づいて治療を調整する精密医療は、ますます重要になってきています。遺伝子および分子プロファイリングの進歩により、特定の治療に対する反応を予測できる特定のバイオマーカーの同定が可能になり、より効果的で個別化された治療計画につながっています。さらに、人工知能と機械学習の臨床への統合により、膨大なデータを分析する能力が強化され、意思決定プロセスが改善されつつあります。もうひとつの大きな動向は、高密度焦点式超音波（HIFU）や凍結療法など、副作用が少なく効果的ながん制御を提供する低侵襲治療の開発です。これらの技術革新は治療成績を向上させるだけでなく、患者固有のアプローチと長期的な疾患管理を優先する新たな治療パラダイムへの道を開いています。

前立腺がん治療薬市場の成長を促進する要因は何か？

前立腺がん治療薬市場の成長は、いくつかの要因によって牽引されています。特に高齢化社会における前立腺がんの罹患率の増加が大きな原動力となっており、効果的な治療法の開発が必要とされています。診断および治療方法における技術の進歩も、早期発見とより正確な治療選択肢を可能にするため、市場の成長を後押ししています。個別化医療の台頭と特定の遺伝的・分子的標的の同定により、治療手段が拡大し、治療成績が向上しています。さらに、官民双方からのがん研究開発への資金提供の増加が、革新的な治療法の導入を加速させています。前立腺がんに対する認識と検診の取り組みの高まりは、診断率の向上とそれに続く治療需要の増加につながっています。これらの要因が相まって、市場情勢はダイナミックに拡大しており、患者の転帰を改善し、がん治療を進歩させる上で重要な役割を担っています。

セグメント

治療タイプ（ホルモン療法、標的療法、化学療法、標的療法）、流通チャネル（病院薬局、小売薬局、オンライン販売、その他の流通チャネル）

調査対象企業の例（注目の76社）

  • AbbVie Inc.
  • Allergan plc
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Debiopharm Group
  • Endo Pharmaceuticals Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genentech Inc.
  • GlaxoSmithKline Plc
  • Janssen Biotech Inc.
  • Novartis AG
  • Pfizer Inc.
  • Progenics Pharmaceuticals Inc.
  • Sanofi S.A.
  • Spectrum Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Limited
  • TOLMAR Pharmaceuticals Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP-1747

Global Prostate Cancer Therapeutics Market to Reach US$26.4 Billion by 2030

The global market for Prostate Cancer Therapeutics estimated at US$18.0 Billion in the year 2024, is expected to reach US$26.4 Billion by 2030, growing at a CAGR of 6.6% over the analysis period 2024-2030. Hormone Therapy, one of the segments analyzed in the report, is expected to record a 6.8% CAGR and reach US$21.0 Billion by the end of the analysis period. Growth in the Targeted Therapy segment is estimated at 5.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$5.0 Billion While China is Forecast to Grow at 6.0% CAGR

The Prostate Cancer Therapeutics market in the U.S. is estimated at US$5.0 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$4.0 Billion by the year 2030 trailing a CAGR of 6.0% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.2% and 5.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.

Global Prostate Cancer Therapeutics Market - Key Trends and Drivers Summarized

What Are the Current Therapeutic Approaches for Prostate Cancer?

Prostate cancer therapeutics encompass a wide range of treatments designed to manage and treat prostate cancer, which is one of the most common cancers among men worldwide. The primary therapeutic approaches include surgery, radiation therapy, hormone therapy, chemotherapy, and more recently, immunotherapy and targeted therapies. Surgical options, such as radical prostatectomy, involve the removal of the prostate gland and are typically recommended for localized cancers. Radiation therapy, delivered either externally or through brachytherapy, targets cancer cells with high-energy rays. Hormone therapy, or androgen deprivation therapy (ADT), reduces the levels of male hormones that fuel prostate cancer growth. Chemotherapy, although less commonly used in early stages, is employed for advanced or hormone-refractory prostate cancers. These treatments are often used in combination to maximize effectiveness and manage the disease more comprehensively.

How Are Emerging Therapies Changing the Landscape of Prostate Cancer Treatment?

Emerging therapies are revolutionizing the treatment landscape for prostate cancer by offering more targeted and personalized treatment options. One of the most promising areas is the development of novel androgen receptor inhibitors, such as enzalutamide and apalutamide, which are more effective in blocking the signals that promote cancer growth. Immunotherapy, particularly the use of immune checkpoint inhibitors, is also gaining traction, although its success in prostate cancer has been more limited compared to other cancers. Another significant advancement is the use of radioligand therapy, such as lutetium-177-PSMA-617, which delivers targeted radiation to prostate-specific membrane antigen (PSMA)-expressing cells. Additionally, PARP inhibitors, like olaparib, have shown efficacy in patients with specific genetic mutations, providing a new avenue for personalized treatment. These innovative therapies are not only improving survival rates but also enhanciwng the quality of life for patients by reducing the side effects associated with traditional treatments.

What Innovations Are Driving the Future of Prostate Cancer Therapeutics?

The future of prostate cancer therapeutics is being shaped by several key innovations and research advancements. Precision medicine, which involves tailoring treatment based on the genetic profile of the individual and their tumor, is becoming increasingly important. Advances in genetic and molecular profiling are enabling the identification of specific biomarkers that can predict response to certain therapies, leading to more effective and individualized treatment plans. Additionally, the integration of artificial intelligence and machine learning in clinical practice is enhancing the ability to analyze vast amounts of data and improve decision-making processes. Another significant trend is the development of minimally invasive treatments, such as high-intensity focused ultrasound (HIFU) and cryotherapy, which offer effective cancer control with fewer side effects. These innovations are not only enhancing therapeutic outcomes but also paving the way for new treatment paradigms that prioritize patient-specific approaches and long-term disease management.

What Factors Are Driving the Growth in the Prostate Cancer Therapeutics Market?

The growth in the prostate cancer therapeutics market is driven by several factors. The increasing incidence of prostate cancer, particularly among aging populations, is a major driver, necessitating the development of effective treatments. Technological advancements in diagnostic and treatment modalities are also propelling market growth, as they enable earlier detection and more precise treatment options. The rise of personalized medicine and the identification of specific genetic and molecular targets are expanding the therapeutic arsenal and improving treatment outcomes. Additionally, increased funding for cancer research and development from both public and private sectors is accelerating the introduction of innovative therapies. The growing awareness and screening initiatives for prostate cancer are leading to higher diagnosis rates and subsequent treatment demand. These factors collectively underscore the dynamic and expanding landscape of the prostate cancer therapeutics market, highlighting its critical role in improving patient outcomes and advancing cancer care.

SCOPE OF STUDY:

The report analyzes the Prostate Cancer Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapy Type (Hormone Therapy, Targeted Therapy, Chemotherapy, Targeted Therapy); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online sales, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 76 Featured) -

  • AbbVie Inc.
  • Allergan plc
  • Amgen Inc.
  • Astellas Pharma Inc.
  • AstraZeneca Plc.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Debiopharm Group
  • Endo Pharmaceuticals Inc.
  • F. Hoffmann-La Roche Ltd.
  • Genentech Inc.
  • GlaxoSmithKline Plc
  • Janssen Biotech Inc.
  • Novartis AG
  • Pfizer Inc.
  • Progenics Pharmaceuticals Inc.
  • Sanofi S.A.
  • Spectrum Pharmaceuticals Inc.
  • Takeda Pharmaceutical Company Limited
  • TOLMAR Pharmaceuticals Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Prostate Cancer Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advances in Precision Medicine Propel Growth in Prostate Cancer Therapeutics
    • Increasing Prevalence of Prostate Cancer Spurs Demand for Advanced Treatments
    • Breakthroughs in Immunotherapy Strengthen Business Case for Prostate Cancer Therapeutics
    • Growing Awareness and Screening Programs Accelerate Demand for Early Treatment Options
    • Hormone Therapy Developments Expand Addressable Market Opportunity
    • Innovations in Radiopharmaceuticals Propel Growth in Prostate Cancer Management
    • Regulatory Approvals of Novel Drugs Drive Adoption of Advanced Prostate Cancer Treatments
    • Increasing Investment in Oncology Research Strengthens Prostate Cancer Therapeutics Market
    • Biopharmaceutical Collaborations and Partnerships Spur Innovation in Prostate Cancer Treatments
    • Aging Population Sustains Growth in Prostate Cancer Therapeutics Market
    • Expanding Use of Combination Therapies Generates Opportunities in Prostate Cancer Treatment
    • Growing Pipeline of Prostate Cancer Drugs Strengthens Market Competitiveness
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Prostate Cancer Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Prostate Cancer Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Prostate Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Hormone Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Hormone Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Online Sales by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Online Sales by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Online Sales by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Prostate Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 26: USA Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: USA 15-Year Perspective for Prostate Cancer Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Targeted Therapy and Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Prostate Cancer Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: Canada 15-Year Perspective for Prostate Cancer Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Targeted Therapy and Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Prostate Cancer Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels for the Years 2015, 2025 & 2030
  • JAPAN
    • Prostate Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 38: Japan Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Japan Historic Review for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Japan 15-Year Perspective for Prostate Cancer Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Targeted Therapy and Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Prostate Cancer Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CHINA
    • Prostate Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 44: China Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: China Historic Review for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: China 15-Year Perspective for Prostate Cancer Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Targeted Therapy and Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 47: China Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Prostate Cancer Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels for the Years 2015, 2025 & 2030
  • EUROPE
    • Prostate Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 51: Europe Historic Review for Prostate Cancer Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Europe 15-Year Perspective for Prostate Cancer Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Prostate Cancer Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Targeted Therapy and Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Prostate Cancer Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels for the Years 2015, 2025 & 2030
  • FRANCE
    • Prostate Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 59: France Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: France Historic Review for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: France 15-Year Perspective for Prostate Cancer Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Targeted Therapy and Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 62: France Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Prostate Cancer Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels for the Years 2015, 2025 & 2030
  • GERMANY
    • Prostate Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 65: Germany Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Germany Historic Review for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: Germany 15-Year Perspective for Prostate Cancer Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Targeted Therapy and Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Prostate Cancer Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 71: Italy Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Italy Historic Review for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Italy 15-Year Perspective for Prostate Cancer Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Targeted Therapy and Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Prostate Cancer Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Prostate Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 77: UK Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: UK Historic Review for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: UK 15-Year Perspective for Prostate Cancer Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Targeted Therapy and Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 80: UK Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Prostate Cancer Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 83: Rest of Europe Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Rest of Europe Historic Review for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Rest of Europe 15-Year Perspective for Prostate Cancer Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Targeted Therapy and Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 86: Rest of Europe Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Rest of Europe Historic Review for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Rest of Europe 15-Year Perspective for Prostate Cancer Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Prostate Cancer Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 89: Asia-Pacific Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Asia-Pacific Historic Review for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Asia-Pacific 15-Year Perspective for Prostate Cancer Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Targeted Therapy and Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 92: Asia-Pacific Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Asia-Pacific Historic Review for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Asia-Pacific 15-Year Perspective for Prostate Cancer Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF WORLD
    • TABLE 95: Rest of World Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Rest of World Historic Review for Prostate Cancer Therapeutics by Therapy Type - Hormone Therapy, Targeted Therapy and Chemotherapy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Rest of World 15-Year Perspective for Prostate Cancer Therapeutics by Therapy Type - Percentage Breakdown of Value Sales for Hormone Therapy, Targeted Therapy and Chemotherapy for the Years 2015, 2025 & 2030
    • TABLE 98: Rest of World Recent Past, Current & Future Analysis for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of World Historic Review for Prostate Cancer Therapeutics by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of World 15-Year Perspective for Prostate Cancer Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Online Sales and Other Distribution Channels for the Years 2015, 2025 & 2030

IV. COMPETITION